

***Fiscal Year 2020 Chronic Pain Management Research Program (CPMRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-20-CPMRP-IIRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports innovative research that will make an original and important contribution to the field of research, patient care, and/or quality of life in one of the FY20 CPMRP IIRA Focus Areas of Chronification of pain and Development of non-μ-opioid receptor-targeted therapies and approaches. • Multidisciplinary collaborations and innovative approaches are encouraged. • Clinical trials will not be funded. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$900,000 for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): August 7, 2020 5:00 p.m. Eastern time</p> <p>Application: November 6, 2020 11:59 p.m. Eastern time</p>
<p>Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-20-CPMRP-TRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports translational research that will accelerate the movement of efficacious, evidence-based ideas into clinical applications. • Research must address one or both of the FY20 CPMRP TRA Focus Areas of Implementation science and Comparative effectiveness. • Effectiveness-implementation hybrid studies that incorporate biopsychosocial models of assessment are encouraged. • Studies seeking to evaluate new therapies or approaches, either pharmacological or non-pharmacological, that have not been previously evaluated in a clinical setting will not be funded. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,400,000 for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): August 7, 2020 5:00 p.m. Eastern time</p> <p>Application: November 6, 2020 11:59 p.m. Eastern time</p>